Form 4 for CHRS Coherus Oncology, Inc.
Accepted 2026-01-26 00:00:00 ET · period of report 2026-01-22 · accession 0001610717-26-000026 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-01-26 | 2026-01-22 | CHRS | McMichael Bryan J | CFO | A - Grant | $0.00 | +112.5K | 133.7K | +530% | $0 |
| D | 2026-01-26 | 2026-01-22 | CHRS | McMichael Bryan J | CFO | A - Grant | $0.00 | +225.0K | 225.0K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-01-22 | A | A | 112,500 | $0.00 | 133,736 | D | — | — | (F1) Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 50% of the RSUs vest on May 20, 2027 and 50% of the RSUs vest on March 20, 2029, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date. |
| 2 | Derivative | Stock Option (Right to Buy) | 2026-01-22 | A | A | 225,000 | $0.00 | 225,000 | D | $1.59 · — to 2036-01-22 | 225,000 Common Stock | (F2) The underlying shares subject to the option vest and become exercisable as to 1/4th of the total number of shares on the one year anniversary of January 22, 2026 and 1/48th of the total number of shares in successive, equal monthly installments thereafter, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date. |